Trial Profile
An open-label, multi-Center, uncontrolled phase II study in patients with Waldenstrom Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Tirabrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 01 Jun 2022 Results of an analysis reporting efficacy and safety two years outcomes published in the Cancer Science
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results (data cut off date- 1 Feb 2021) assessing two-year follow-up data of this study, presented at the 63rd American Society of Hematology Annual Meeting and Exposition